An Open-Label, Multicenter, Phase I/II Study of JNJ-40346527, a CSF-1 R Inhibitor, in Patients with Relapsed or Refractory Hodgkin Lymphoma - von Tresckow, B; Morschhauser, F; Ribrag, V (Clin Cancer Res, 2015)
et al.